Obstructive sleep apnea and the metabolic syndrome

Expert Review of Respiratory Medicine

Volumn 3, Issue 2, 2009, Pages 177-186

  Lam, Jamie C M ^a   Ip, Mary S M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Glucose metabolism; Hypertension; Metabolic syndrome; Obstructive sleep apnea

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DAYTIME SOMNOLENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRINKING BEHAVIOR; DYSLIPIDEMIA; EVIDENCE BASED PRACTICE; GLUCOSE METABOLISM; HUMAN; HYPOXEMIA; HYPOXIA; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; SMOKING; SYMPATHETIC FUNCTION;

EID: 69949154199     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.10     Document Type: Review

References (131)

1. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc. Am. Thorac. Soc. 5, 136-143 (2008).
2. Lumeng JC, Chervin RD. Epidemiology of pediatric obstructive sleep apnea. Proc. Am. Thorac. Soc. 5, 242-252 (2008).
3. Iber C, Ancoli-Israel S, Chesson Jr AL, Quan SF. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. American Academy of Sleep Medicine, IL, USA (2007).
4. Young T, Palta M, Dempsey J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 328, 230-235 (1993).
5. Bearpark H, Elliott L, Grunstein R et al. Snoring and sleep apnea: a population study in Australian men. Am. J. Respir. Crit. Care Med. 163, 608-613 (1995).
6. Ip MSM, Lam B, Tang LC, Lauder IJ et al. A community study of sleep-disordered breathing in middle-aged Chinese women in Hong Kong: prevalence and gender differences. Chest 125, 127-134 (2004).
7. Kim JK, In KH, Kim JH et al. Prevalence of sleep-disordered breathing in middleaged Korean Men and Women. Am. J. Respir. Crit. Care Med. 170, 1108-1113 (2004).
8. Udwadia ZF, Doshi AV, Lonhar SG, Singh CL. Prevalence of sleep disordered breathing and sleep apnea in middle-aged urban Indian men. Am. J. Respir. Crit. Care Med. 169, 168-173 (2004).
9. Sharma SK, Kumpawat S, Banga A, Goel A. Prevalence and risk factors of obstructive sleep apnea syndrome in a population of Delhi, India. Chest 130, 149-156 (2006).
10. Duran J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 years. Am. J. Respir. Crit. Care Med. 163, 685-689 (2001).
11. Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: prevalence and severity. Am. J. Respir. Crit. Care Med. 157, 144-148 (1998).
12. Kohler MJ, van den Heuvel CJ. Is there a clear link between overweight/ obesity and sleep disordered breathing in children? Sleep Med. Rev. 12, 347-361 (2008).
13. McNicholas WT, Bonsignore MR and the Management Committee of EU COST ACTION B26. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur. Respir. J. 29, 156-178 (2007).
14. Marin JM, Carrizo SJ, Vicente L, Agusti AGN. Long term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365, 1046-1053 (2005).
15. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea - a 7-year follow up. Am. J. Respir. Crit. Care Med. 166, 159-165 (2002).
16. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365, 1415-1428 (2005).
17. American Medical Association. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285, 2486-2497 (2001).
18. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 366, 1059-1062 (2005).
19. WHO Expert Consultation. Appropriate BMI for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403), 157-163 (2004).
20. WHO. Obesity: preventing and managing the global epidemic. WHO Technical report series 894. Presented at: WHO Consultation on Obesity. Geneva, Switzerland, 3-5 June 1997.
21. Borona E, Kiechl S, Willeit J et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross sectional data from the Bruneck Study. Int. J. Obese. 27, 1283-1289 (2003).
22. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 33, 351-375 (2004).
23. Gale EA, Alberti KGMM. Should we dump the metabolic syndrome? BMJ 336, 640-642 (2008).
24. Satter N, McConnachie A, Sharper G et al. Can metabolic syndromes usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371(9628), 1927-1935 (2008).
25. Wilcox I, McNamara SG, Collins FL, Grunstein RR, Sullivan CE. 'Syndrome Z': the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax 53, S25-S28 (1998).
26. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med. Rev. 9, 211-224 (2005).
27. Coughlin SR, Mawdsley L, Mugarza JA et al. Obstructive sleep apnea is independently associated with an increased prevalence of metabolic syndrome. Eur. Heart J. 25, 735-741 (2004).
28. Gruber A, Horwood F, Sithole J, Ali NJ, Idris I. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc. Diabetol. 5, 22 (2006).
29. Lam JCM, Lam B, Lam CL et al. Obstructive sleep apnea and the metabolic syndrome in community-based Chinese subjects in Hong Kong. Resp. Med. 100(6), 980-987 (2006).
30. Sasanabe R, Banno K, Otake K et al. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. Hypertens. Res. 29, 315-322 (2006).
31. Cho N, Joo S, Kim J et al. Relation of habitual snoring with components of metabolic syndrome in Korean adults. Diabetes Res. Clin. Pract. 71, 256-263 (2006).
32. Parish JM, Adam T, Facchiano L et al. Relationship of metabolic syndrome and obstructive sleep apnea. J. Sleep Med. 3, 467-472 (2007).
33. Salord N, Mayos M, Miralda R, Perez A. Respiratory sleep disturbances in patients undergoing gastric bypass surgery and their relation to metabolic syndrome. Obes. Surg. 19(1), 74-79 (2008).
34. Kono M, Tatsumi K, Saibara T et al. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 131, 1387-1392 (2007).
35. Sharma SK, Kumpawat S, Goel A, Banga A, Ramakrishnan L, Chaturvedi P. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med. 8, 12-17 (2007).
36. Couglin SR, Mawdsley L, Mugarza JA, Wilding JPH, Calverley PMA. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur. Respir. J. 29, 720-727 (2007).
37. Ambrosetti M, Lucioni AM, Conti S, Pedretti RF, Neri M. Metabolic syndrome in obstructive sleep apnea and related cardiovascular risk. J. Cardiovasc. Med. (Hagerstown) 7, 826-829 (2006).
38. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 134, 686-692 (2008).
39. Schwartz AR, Patil SP, Laffan AM, Polotsky VY, Schneider H, Smith PL. Obesity and obstructive sleep apnea: pathogenic mechanism and therapeutic approaches. Proc. Am. Thorac. Soc. 5 (2), 185-192 (2008).
40. de Sousa AGP, Cercato C, Mancini MC, Halpern A. Obesity and obstructive sleep apnea. Obes. Rev. 9, 340-354 (2008).
41. Vgontzas AN, Papanicolaou DA, Bixler EO et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J. Clin. Endocrinol. Metab. 85(3), 1151-1158 (2000).
42. Peppard PE, Young T, Palta M, Dempsey J, Skareyd J. Longitudinal study of moderate weight change and sleepdisordered breathing. JAMA 284, 3015-3021 (2000).
43. Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 1(3), e62 (2004).
44. Chin K, Shimizu K, Nakamura T et al. Changes in intra-abdominal fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 100, 706-712 (1999).
45. Lam JCM, Lam B, Yao TJ et al. A doubleblind randomized controlled trial of nasal continuous positive airway pressure treatment on insulin sensitivity in men with obstructive sleep apnea. Respirology 13(Suppl. 5), A135 (2008).
46. Lam B, Sam K, Mok WY et al. Randomised study of three non-surgical treatments in mild to moderate obstructive sleep apnoea. Thorax 62(4), 354-359 (2007).
47. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes. Res. 6(Suppl. 2), 51S-209S (1998).
48. Fritscher LG, Mottin CC, Canani S, Chatkin JM. Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obes. Surg. 17(1), 95-99 (2007).
49. Young T, Peppard P, Palta M et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch. Intern. Med. 157(15), 1746-1752 (1997).
50. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 342(19), 1378-1384 (2000).
51. Nieto FJ, Young TB, Lind BK et al. Association of sleep-disordered breathing, and hypertension in a large community-based study. JAMA 283, 1829-1836 (2000).
52. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnea syndrome as a risk factor for hypertension: population study. BMJ 320, 479-482 (2000).
53. Bixler EO, Vgontzas AN, Lin HM et al. Association of hypertension and sleepdisordered breathing. Arch. Intern. Med. 160, 2289-2295 (2000).
54. Davies C, Crosby J, Mullins R et al. Case-control study of 24 hour ambulatory blood pressure in patients with obstructive sleep apnea and normal matched control subjects. Thorax 55, 736-740 (2000).
55. Li AM, Au CT, Sung RY et al. Ambulatory blood pressure in children with obstructive sleep apnoea: a community based study. Thorax 63(9), 803-809 (2008).
56. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in sleep apnea hypopnea syndrome. Am. J. Respir. Crit. Care Med. 163, 344-348 (2001).
57. Pepperell JC, Ramitassingh-Dow S, Crostheaite N et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnea: a randomized parallel trial. Lancet 359, 204-210 (2002).
58. Becker HF, Jerrentrup A, Ploch T et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107, 68-73 (2003).
59. Campos-Rodriguez, Grilo-Reina A, Perez-Ronchel J et al. Effect of continuous positive airway pressue on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest 129, 1459-1467 (2006).
60. Hui DS, To KW, Ko FW et al. Nasal CPAP reduces systemic blood pressure in patients with obstructive sleep apnoea and mild sleepiness. Thorax 61(12), 1083-1090 (2006).
61. Haentijens P, Van Meerhaeghe A, Moscariello A et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome - evidence from a meta-analysis of placebo-controlled randomized trials. Arch. Intern. Med. 167, 757-765 (2007).
62. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive pressure on blood pressure in obstructive sleep apnea. Hypertension 50, 417-423 (2007).
63. Alajmi M, Mulgrew AT, Fox J et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. Lung 185, 67-72 (2007).
64. Barnes M, Houston D, Worsnop CJ et al. A randomized controlled trial of continuous positive airway pressure in mild obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 165(6), 773-780 (2002).
65. Barbé F, Mayoralas LR, Duran J et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann. Intern. Med. 134(11), 1015-1023 (2001).
66. Robinson GV, Smith DM, Langford BA et al. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur. Resp. J. 27, 1229-1235 (2006).
67. Ip MS. Obstructive sleep apnoea, insulin resistance and sleepiness. Thorax 63(11), 939-940 (2008).
68. Börntorp P. Metabolic implications of body fat distribution. Diabetes Care 14, 1132-1143 (1991).
69. Tasali and Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc. Am. Thorac. Soc. 5(2), 207-217 (2008).
70. Ip MSM, Lam B, Ng MMT, Lam WK, Tsang KWT, Lam KSL. Obstructive sleep apnea is independently associated with insulin resistance. Am. J. Respir. Crit. Care Med. 165, 670-676 (2002).
71. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE. Sleep disordered breathing, glucose intolerance, insulin resistance: the Sleep Heart Health Study. Am. J. Epidemiol. 160, 521-530 (2004).
72. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and Type II diabetes: a population-based study. Am. J. Respir. Crit. Care Med. 172, 1590-1595 (2005).
73. Harsch IA, Schahin SP, Radespiel-Tröger FN et al. Continuous positive airway pressure treatment rapidly improves insulin resistance in patients with obstructive sleep apnea syndrome. Am. J. Respir. Crit. Care Med. 169, 156-162 (2004).
74. Schahin SP, Nechanitzky T, Dittel C et al. Long-term improvement of insulin sensitivity during CPAP therapy in the obstructive sleep apnoea syndrome. Med. Sci. Monit. 14(3), CR117-CR121 (2008).
75. Barcelo A, Barbe F, de la Pena M et al. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 63, 946-950 (2008).
76. Punjabi NM, Beamer BA. Alterations in glucose disposal in sleep-disordered breathing. Am. J. Respir. Crit. Care Med. 179(3), 235-240 (2009).
77. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and Type 2 diabetes. Thorax 62(11), 969-974 (2007).
78. Anderson AJ, Sobocinski KA, Freedman DS et al. Body fat distribution, plasma lipids and lipoproteins. Arteriosclerosis 8, 88-94 (1998).
79. Newman AB, Nieto FJ. Relationship of sleep-disordered breathing to cardiovascular risk factors. The Sleep Heart Health Study. Am. J. Epidemiol. 154, 50-59 (2001).
80. Ip MSM, Lam KSL, Ho CM, Tsang KWT, Lam WK. Serum leptin and vascular risk factors in OSA. Chest 118(3), 580-586 (2000)
81. Schafer H, Pauleit D, Sudhop T, Gouni-Berthold I, Ewig S, Berthold HK. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest 122, 829-839 (2002).
82. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 175, 190-195 (2007).
83. Borgel J, Sanner BM, Bittlinsky A et al. Obstructive sleep apnoea and its therapy influence high density lipoprotein cholesterol serum levels. Eur. Respir. J. 27, 121-127 (2006).
84. Robinson GV, Pepperrell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep data from randomized controlled trials. Thorax 59(9), 777-782 (2004).
85. Steinberg D. Low density lipoprotein oxidation and its pathological significance. J. Biol. Chem. 272, 20963-20966 (1997).
86. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AGN. Abnormal lipid peroxidation in patients with sleep apnea. Eur. Respir. J. 16, 644-647 (2000).
87. Lavie L. Oxidative stress - a unifying paradigm in obstructive sleep apnea and comorbidities. Prog. Cardiovasc. Dis. 51(4), 303-312 (2009).
88. Tan KCB, Chow WS, Lam JC et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 184(2), 377-382 (2006).
89. Jun J, Polotsky VY. Sleep disordered breathing and metabolic effects: evidence from animal models. Sleep Med. Clin. 2, 263-277 (2007).
90. Somers VK, Dyken ME, Clary MP et al. Sympathetic neural mechanisms in OSA. J. Clin. Invest. 96, 1897-1904 (1995).
91. Grassi G, Facchini A, Trevano FQ et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46, 321-325 (2005).
92. Wolk R, Shamsuzzaman, Somers VK. Obesity, sleep apnea and hypertension. Hypertension 42, 1067-1074 (2003).
93. Dopp JM, Pharma D, Reichmuth KJ, Morgan B. Obstructive sleep panea and hypertension: mechanisms, evaluation and managment. Central Hypertension Reports 9, 529-534 (2007).
94. Moller DS, Lind P, Strunge B et al. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am. J. Hypertens. 16, 274-280 (2003).
95. Pratt-Ubunama MN, Nichizaka MK, Boedefeld RL et al. Plasma aldosterone is related to severity of obstructive sleep apnea subjects with resistant hypertension. Chest 131, 453-459 (2007).
96. Chan SLF, Pernett CW, Morgan NG. Differential expression of a2-adrenoceptor subtypes in purified rat pancreatic islet A- and B-cells. Cell Signal. 9, 71-78 (1997).
97. Lam JC, Xu A, Tam S et al. Hypoadiponectinemia is related to sympathetic activation and severity of obstructive sleep apnea. Sleep 31(12), 1721-1727 (2008).
98. Iiyori N, Alonso LC, Li J et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am. J. Respir. Crit. Care Med. 175, 851-857 (2007).
99. Cooper VL, Pearson SB, Bowker CM, Elliott MW, Hainsworth R. Interaction of chemoreceptor and baroreceptor reflexes by hypoxia and hypercapnia - a mechanism for promoting hypertension in obstructive sleep apnoea. J. Physiol. 568(Pt 2), 677-687 (2005).
100. Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of Type 2 diabetes. Diabetes Care 29, 657-661 (2006).
101. Ip MSM, Mokhlesi B. Sleep and glucose intolerance/diabetes mellitus. Sleep Med. Clin. 2, 19-29 (2007).
102. Van Cauter E, Holmback U, Knutson K et al. Impact of sleep and sleep loss on neuroendocrine and metabolic function. Horm. Res. 67, 2-9 (2007).
103. Dadoun F, Darmon P, Achard V et al. Effect of sleep apnoea syndrome on the circadian profile of cortisol in obese men. Am. J. Physiol. Endocrinol. Metab. 293, E466-E474 (2007).
104. Trakada G, Chrousos G, Pejovic S, Vgontzas A. Sleep apnea and its association with the stress system, inflammation, insulin resistance and visceral obesity. Sleep Med. Clin. 2, 251-261 (2007).
105. Suzuki YJ, Jain V, Park AM, Day RM. Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. Free Radic. Biol. Med. 40, 1683-1692 (2006).
106. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br. J. Nutr. 100, 227-235 (2008).
107. Polotsky VY, Li J, Punjabi NM et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J. Physiol. 552, 253-264 (2003).
108. Li J, Savransky V, Nanayakkara A, Smith PL, O'Donnell CP, Polotsky VY. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J. Appl. Physiol. 102, 557-563 (2007).
109. Jun J, Savransky V, Nanayakkara A et al. Intermittent hypoxia has organ-specific effects of oxidative stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295(4), R1274-R1281 (2008).
110. Ip MSM, Lam B, Chan LY et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am. J. Respir. Crit. Care Med. 162, 2166-2171 (2000).
111. Schulz R, Mahmoudi S, Hattar K et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Am. J. Respir. Crit. Care Med. 162, 566-570 (2000).
112. Jordan W, Cohrs S, Degner D et al. Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome. J. Neural Transm. 113, 239-254 (2006).
113. Sutherland J, McKinnley B, Eckel RH. The metabolic syndrome and inflammation. Metabolic Syndr. Rel. Disord. 2, 82-104 (2004).
114. Hotamisligil GS. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
115. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96, 939-949 (2005).
116. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 580, 2917-2921 (2006).
117. Lefebvre B, Pípin JL, Baguet JP et al. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur. Respir. J. 32(1), 113-120 (2008).
118. Hui DS, Ko FW, Fok JP et al. The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 125, 1768-1775 (2004).
119. Chin K, Nakamura T, Shimizu K et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am. J. Med. 109, 562-567 (2000).
120. Yokoe T, Minoguchi K, Matsuo H et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107, 1129-1134 (2003).
121. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-kBdependent genes in obstructive sleep apnea syndrome. Am. J. Respir. Crit. Care Med. 174, 824-830 (2006).
122. Punjabi NM, Beamer BA. C-reactive protein is associated with sleep disordered breathing independent of adiposity. Sleep 30, 29-34 (2007).
123. von Kanel R, Loredo JS, Ancoli-Israel S, Mills PJ, Dimsdale JE. Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. Metabolism 56, 969-976 (2007).
124. Peled N, Kassirer M, Shitrit D et al. The association of OSA with insulin resistance, inflammation and metabolic syndrome. Res. Med. 101, 1696-1701 (2007).
125. Gozal D, Serpero LD, Capdevila OS, Kheirandish-Gozal L. Systemic inflammation in non-obese children with obstructive sleep apnea. Sleep Med. 9, 254-259 (2008).
126. Lam DCL, Xu A, Lam KSL et al. Serum adipocyte-fatty acid binding protein (A-FABP) level is elevated in severe obstructive sleep apnea (OSA) and correlates with insulin resistance. Eur. Respir. J. 33, 346-351 (2009).
127. Polotsky VY, Smaldone MC, Scharf MT et al. Impact of interrupted leptin pathways on ventilatory control. J. Appl. Physiol. 96(3), 991-998 (2004).
128. Patel SR, Palmer LJ, Larkin EK, Jenny NS, White DP, Redline S. Relationship between obstructive sleep apnea and diurnal leptin rhythms. Sleep 27, 235-239 (2004).
129. Sanner BM, Kollhosser P, Buechner N, Zidek W, Tepel M. Influence of treatment on leptin levels in patients with obstructive sleep apnoea. Eur. Respir. J. 23, 601-604 (2004).
130. Gozal D, Kheirandish-Gozal L. Cardiovascular morbidity in obstructive sleep apnea-oxidative stress, inflammation, and much more. Am. J. Respir. Crit. Care Med. 177, 369-375 (2008).
131. Riha RL, Diefenbach K, Jennum P, McNicholas WT; Management Committee COST B26 Action on Sleep Apnoea Syndrome. Genetic aspects of hypertension and metabolic disease in the obstructive sleep apnoea-hypopnoea syndrome. Sleep Med. Rev. 12(1), 49-63 (2008).